CN1132597C - The active part of golden pheasant as one Chinese medicine material and its application in preparing medicinal composite - Google Patents
The active part of golden pheasant as one Chinese medicine material and its application in preparing medicinal composite Download PDFInfo
- Publication number
- CN1132597C CN1132597C CN00111784A CN00111784A CN1132597C CN 1132597 C CN1132597 C CN 1132597C CN 00111784 A CN00111784 A CN 00111784A CN 00111784 A CN00111784 A CN 00111784A CN 1132597 C CN1132597 C CN 1132597C
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- active part
- golden pheasant
- application
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention provides an active site (Hu-ECS) of caragana sinica as a traditional Chinese medicine and an extraction method thereof. The extraction method comprises the processes such as alcohol extraction, aqueous extract, chromatography, etc. Simultaneously, the present invention also provides a method for preparing a suitable preparation by directly using the active site or by mixing the active site and solids or liquids usually used for preparations in pharmacy. The present invention also relates to the application of the caragana sinica active site preparation in preventing and treating primary osteoporosis and female menopausal syndrome.
Description
The invention relates to from the root of population pattern changes such as Chinese herbal medicine caragana and Flos Carthami caragana and to extract active site and make medicine and be used to prevent and treat primary osteoporosis and menopausal syndrome.
Primary osteoporosis and menopausal syndrome are the health problems that has a strong impact on quality of life later in numerous women's middle age, and establishing prevention and Therapeutic Method is the focus of medical research.Supplement therapys such as the main at present use calcium preparation of primary osteoporosis, vitamin D, calcitonin and estrogen, Drug therapys such as estrogen antagonist Reynolds former times sweet smell (Renoxifen), hydroxyl phosphine class, prevention effect is also unsatisfactory.Menopausal syndrome is mainly used controversies in hormone replacement in the elderly.Because life-time service estrogen can increase the danger that suffers from breast cancer with carcinoma of endometrium, use to be subjected to necessarily placing restrictions on.In recent years, from enriching the natural drug that nature exists, especially from traditional Chinese herbal medicine, seek the control medicine and caused extensive concern.
The active site and the extracting method thereof that the purpose of this invention is to provide Chinese medicine caragana (Caragana sinica) and Flos Carthami caragana (Caragana Rosea) root.
Another object of the present invention is with the raw material of above-mentioned active site as pharmaceutical preparation.
A further object of the invention provide above-mentioned active site preparation control primary osteoporosis and menopause the syndrome medicament compositions application.
Chinese herbal medicine Radix Caraganae Sinicae of the present invention is the dry root of pulse family caragana, records the earliest in supplementary Amplifications of the Compendium of Materia Medica and herbal for Relief of Famines ancient books, is used for traumatic injury in the Shanghai City Chinese crude drug standard (version in 1994), the body edema that wets, treatments such as rheumatalgia.
The present invention records by a large amount of chemistry and pharmacological research, the root of root of Chinese medicine caragana (having another name called Radix Caraganae Sinicae) and congener Radix Caraganae Roseae contains abundant oligomeric diphenylethylene and osajin composition, and these compositions concentrate on a specific part (be called for short Hu-ECS) of extract, and this position can be used as the raw material of pharmaceutical preparation.
The present invention extracts active site by following method:
1. get the dry root of caragana or Radix Caraganae Roseae, the back decocting with 80-100 ℃ of pulverizing boils or the ethanol (or methanol) of 50%-95% extracts.
2. decocting medicinal liquid concentrated solution is with the pure soluble fraction of 60%-95% dissolve with ethanol, and the extractum of ethanol or methanol extraction stirs with 3-20 times of water gaging, gets it and precipitates part.
3. above-mentioned pure soluble fraction or water precipitation part through vacuum drying or spray drying, are used the silica gel inspection, and the position of wherein containing between two speckles of Kobophenol A and α-viniferin accounts for the full weight ratio of dry product between 30%-80%.
The active site that extracts according to said method is through silica gel column chromatography and R18 reversed-phase silica gel chromatography, therefrom and be separated to 6 kinds of oligomeric diphenylethylene compounds: α-viniferin, Miyabenol C, Pallidol, Caraphenol, Isoampelopsin F and KobophenolA.
Above-mentioned active site silica gel thin-layer chromatography, chloroform: methanol (4: 1) launches, and the ferric chloride reagent colour development gets two main dirty green speckles, R
fValue is respectively about 0.30 and 0.20, and the former is α-viniferin, and the latter is Kobophenol A.
Above-mentioned active site is measured with HPLC, uses the ODS post, acetic acid-sodium-acetate buffer of pH4.56: methanol (53: 47), at 15-18 ℃, flow velocity 1ml/min detects wavelength 279nm.α-viniferin can obtain fine the separation and detection with Kobophenol A.
The extract dried powder of active part of golden pheasant as one of the present invention can be used as medicine material and makes capsule, tablet, powder and compound preparation.
Prove through zoopery and clinical treatment result, active part of golden pheasant as one shows the effect of phytoestrogen sample to mice, rat osteoblast there is the effect that promotes propagation, can prevent the bone density of spay rat to descend and the change of bone metabolism standard, the capsule of active part of golden pheasant as one is through clinical trial, and women's the back and the gonalgia has positive effect after menopause to improving.
Below enumerate embodiment and be described more specifically the present invention, composition shown in the embodiment, ratio, operating condition and sequential scheduling can suitably changes in the qualification that does not break away from spirit of the present invention.
Embodiment 1
Caragana root or Radix Caraganae Roseae root coarse powder (hereinafter to be referred as crude drug) 10kg carry secondary with 85% above ethanol (or methanol) heat, each 2 hours, are evaporated to extractum below 60 ℃.After extractum is mixed 100-200 order silica gel, silicagel column on the well-established law, use the chloroform eluting, discard the chloroform eluate, use chloroform-acetone (contain 1% acetone-full acetone) eluting then, the thin layer chromatography inspection, collecting and occuring to stream part that Kobophenol A speckle washes substantially from α-viniferin speckle is effective site, vacuum drying gets powder, about 0.25kg.
Embodiment 2
Crude drug 10kg carries secondary with 85% above ethanol or methanol heat, and each 2 hours, concentrating under reduced pressure got extractum below 60 ℃.Silicagel column on the well-established law is used chloroform-methanol (or ethanol) eluting instead behind petroleum ether-ether (1: 1) eluting, carry out the thin layer chromatography inspection with embodiment 1, and effective site vacuum or spray drying get powder, yield 0.15-0.32kg.
Embodiment 3
Crude drug 10kg, the diafiltration after 1-2 days with 80% above ethanol or methanol merceration is collected 8-12 and is doubly measured percolate, is evaporated to extractum below 60 ℃, about 0.3-0.8kg, extractum is doubly measured petroleum ether (60-90 ℃) with 2-3 and is stirred, and divides and removes petroleum ether layer, and remaining extractum is got 6-20 and doubly measured edged stirring in hot water limit more than 40 ℃, staticly settle, filter, precipitate vacuum or spray drying get about dry powder 0.25kg.
Embodiment 4
Crude drug 10kg fries in shallow oil with hot water and to carry three times, adds 10 times of amounts of water for the first time, boiled 3 hours, second and third time adds 8 times of amounts of water, boils 2 hours, filtered while hot, it is about 1.2 extractum that filtrate decompression is concentrated into density, and adding ethanol to determining alcohol is 70%, staticly settles after stirring evenly more than 16 hours, the supernatant concentrating under reduced pressure gets extractum, equivalent ethyl acetate extraction three times of this extractum, acetic acid ethyl acetate extract concentrates final vacuum or spray drying, gets about dry powder 0.2kg.
Embodiment 5
Get exsiccant caragana effective part extract dried powder, cross 60 mesh sieves, add an amount of microcrystalline Cellulose, starch or other excipient, make dosage forms for oral administration such as capsule, tablet, powder, granule, pill according to a conventional method respectively.
Embodiment 6
The phytoestrogen effect of test the present invention's active part of golden pheasant as one.
Get the adult female mice of 18-22g, extract the both sides ovary, have a rest and carry out vaginal smear after 5 days, once a day, a continuous week, whether extract fully to check ovary, select vaginal smear and do not have Keratinocytic mice and be used for testing, be divided into 4 groups at random by table 1, each group is successive administration 30 days respectively, once a day, simultaneously every day vaginal smear once, 24 hours execution animals after the last time administration, take out the uterus, peel off fatty tissue on every side, the filter paper suck dry moisture, weigh and be converted into 10g body weight uterus weight, the results are shown in Table 1:
Table 1 Hu-ECS estrogen action (the group dosed administration animal keratinocyte incidence rate of x ± sd)
*Uterus weight P value
(g/kg) approach is counted I II III IV (mg/10g body weight) 0.5%CMC-ig 11 0000 3.546 ± 1.173Hu-ECS 0.6 ig 12 17% 17% 00 5.187 ± 1.131 P＜0.01Hu-ECS 0.25 ig 11 36% 000 5.014 ± 2.097 P＞0.05 oestradiol benzoate, 0.5 a μ g/ sc, 13 000 100% 39.421 ± 11.286 P＜0.01
*Percentage rate＜25% that keratinocyte occurs is I;＜50% is II;＜75% is III;＜100% is IV.
Above result of the test shows that Hu-ECS can increase the uterus weight of removal ovary mice, and the vaginal smear keratinocyte mainly shows as the I-II level, but it is extremely short to hold time, and positive incidence rate is lower than 36%, and prompting Hu-ECS has the effect of phytoestrogen sample.
Embodiment 7
Hu-ECS is to the preliminary observation of female ovariectomized rat osteoporosis preventive and therapeutic effect.
With 1 age SD female rats, played perfusion on the 3rd day after the oophorectomize, once a day, put to death after continuous 3 months, test relevant bone metabolism index, the result shows that the bone metabolism index of administration group obtains improvement in various degree, and is close with the improvement degree of nilestriol group.Hu-ECS dosage: L:0.275g/kg, M:0.55g/kg, H:1.10g/kg.
Femur dry weight, ash heavily reach intracellular calcium content change (x ± sd) after table 2 medication
Group dry weight ash triple superphosphate
(g/cm
3) (g/cm
3) g/m
3) A normal control 1.208 ± 0.065
*0.907 ± 0.062
* *0.415 ± 0.028
*B cuts ovum contrast 1.113 ± 0.081 0.780 ± 0.041 0.385 ± 0.015C and cuts ovum+medicine (L) 1.202 ± 0.047
*0.830 ± 0.050
*0.417 ± 0.034
*D cuts ovum+medicine (M) 1.188 ± 0.059
*0.828 ± 0.045
*0.406 ± 0.023
*E cuts ovum+medicine (H) 1.172 ± 0.048 0.810 ± 0.043 0.386 ± 0.022F and cuts ovum+nilestriol 1.200 ± 0.078
*0.849 ± 0.069
*0.405 ± 0.019
*Annotate: n=10
With cut the ovum matched group relatively: * P＜0.05 * * P＜0.01 * * * P＜0.001
Variable density behind the bone after table 3 medication
Group whole body BMD (g/cm
2) femur BMD (g/cm
2)
(n=8) (n=10) A normal control 0.404 ± 0.025
*0.234 ± 0.024B cuts ovum contrast 0.375 ± 0.012 (7.2) 0.223 ± 0.027 (4.7) and cuts ovum+medicine (L) 0.397 ± 0.018 with A than C
*(+5.3) 0.230 ± 0.018 (+3.1) are cut ovum+medicine (M) 0.396 ± 0.018 with B than D
*(+5.6) 0.231 ± 0.021 (+3.6) and B cut ovum+medicine (H) 0.387 ± 0.024 (+3.2) 0.220 ± 0.019 (0.4) and B than E and cut ovum+nilestriol 0.386 ± 0.018 (+2.9) 0.224 ± 0.028 (+0.4) and B than annotating than F: with cut the ovum matched group relatively:
*P＜0.05
() is increase and decrease %
Respectively organize bone trabecula area metering (x ± sd) after table 4 medication
Group vertebral body tibia
(μ m
2/ open country) (μ m
2/ open country)
A normal control 4.284 ± 0.661
* *3.906 ± 0.354
* *
B cuts ovum contrast 1.487 ± 0.218 1.204 ± 0.264
C cuts ovum+medicine (L) 2.328 ± 0.536
* *2.732 ± 0.962
* *
D cuts ovum+medicine (M) 2.030 ± 0.827 2.459 ± 0.541
* *
E cuts ovum+medicine (H) 2.166 ± 0.412
* *2.049 ± 0.517
* *
F cuts ovum+nilestriol 2.728 ± 0.743
* *2.403 ± 0.470
* *
Annotate: with cut the ovum matched group relatively:
* *P＜0.001
n＝9
Embodiment 8
The effective site of caragana is made capsule (220mg/ grain), observe influence the postmenopausal women, wherein administration group 18 examples, age 54-68 year, menopause is more than 2 years, matched group 16 examples, age 49-70 year, menopause is more than 2 years.The administration group, every days 2, capsules was divided early, late secondary is oral, adds 300mg calcium hydrogen phosphate every day.Matched group, the clothes placebo adds 300mg calcium hydrogen phosphate every day, the observation of taking medicine through 3 months, the back and the gonalgia of administration group have clear improvement, and effective percentage does not have obvious change to hepatic and renal function, electrocardiogram more than 85%.
Claims (5)
1, a kind of Chinese medicine active part of golden pheasant as one is characterized in that extracting by following method, in turn includes the following steps: 1. get the dry root of caragana or Radix Caraganae Roseae, pulverize that boil with 80-100 ℃ decocting the back or ethanol or the methanol extraction of 50%-95%; 2. decocting medicinal liquid concentrated solution 60%-95% dissolve with ethanol gets pure soluble fraction; And the extractum of ethanol or methanol extraction stirs with 3-20 times of water gaging, gets its precipitation part; 3. above-mentioned pure soluble fraction or water precipitation part are used the silica gel thin-layer inspection through vacuum drying or spray drying, and the position of wherein containing between two speckles of Kobophenol A and α-viniferin accounts for the full weight ratio of dry product between 30%-80%.
2, by the described Chinese medicine active part of golden pheasant as one of claim 1, it is characterized in that, make capsule, tablet, granule, pill or powder and compound preparation as raw material with described active site dried powder.
3, by the described Chinese medicine active part of golden pheasant as one of claim 1, the application in the medicine of preparation promotion Oesteoblast growth.
4, by the described Chinese medicine active part of golden pheasant as one of claim 1, the application in preparation control primary osteoporosis medicine.
5,, prevent and treat application in the menopausal syndrome medicine in preparation by the described Chinese medicine active part of golden pheasant as one of claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN00111784A CN1132597C (en) | 2000-03-02 | 2000-03-02 | The active part of golden pheasant as one Chinese medicine material and its application in preparing medicinal composite |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN00111784A CN1132597C (en) | 2000-03-02 | 2000-03-02 | The active part of golden pheasant as one Chinese medicine material and its application in preparing medicinal composite |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1269213A CN1269213A (en) | 2000-10-11 |
| CN1132597C true CN1132597C (en) | 2003-12-31 |
Family
ID=4581680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN00111784A Expired - Fee Related CN1132597C (en) | 2000-03-02 | 2000-03-02 | The active part of golden pheasant as one Chinese medicine material and its application in preparing medicinal composite |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1132597C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017003190A1 (en) * | 2015-06-30 | 2017-01-05 | (주)셀트리온 | Whitening cosmetic composition comprising caragana sinica root extract |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102590430B (en) * | 2012-01-17 | 2014-08-13 | 西藏奇正藏药股份有限公司 | Method for detecting liuwei caragana preparation |
| CN103467476B (en) * | 2012-10-15 | 2016-08-10 | 丽水市农业科学研究院 | Resveratrol trimer compounds and preparation method thereof and anticancer usage |
| CN109998097A (en) * | 2019-04-22 | 2019-07-12 | 吉林省华惠生物科技有限公司 | It is a kind of for improving the health care product and preparation method of Woman climacteric symptom |
-
2000
- 2000-03-02 CN CN00111784A patent/CN1132597C/en not_active Expired - Fee Related
Non-Patent Citations (4)
| Title |
|---|
| 中国医院药学杂志1985,5(7) 1985-07-30 林贤琦等锦鸡儿有效成分的分离鉴定 * |
| 中国医院药学杂志1985,5(7) 1985-07-30 林贤琦等锦鸡儿有效成分的分离鉴定;中药能报1988,13(12) 1988-12-31 贾世山等中间锦鸡儿根异黄酮的分离鉴定;中药通报1988,13(12) 1988-12-31 贾世山等中间锦鸡儿根异黄酮的分离鉴定 * |
| 中药能报1988,13(12) 1988-12-31 贾世山等中间锦鸡儿根异黄酮的分离鉴定 * |
| 中药通报1988,13(12) 1988-12-31 贾世山等中间锦鸡儿根异黄酮的分离鉴定 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017003190A1 (en) * | 2015-06-30 | 2017-01-05 | (주)셀트리온 | Whitening cosmetic composition comprising caragana sinica root extract |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1269213A (en) | 2000-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101396428B (en) | Tibetan capillary extract and preparation method, medicine composition and use thereof | |
| JP2023525739A (en) | Chinese herbal composition for treating novel coronavirus pneumonia, its preparation method, its detection method and its use | |
| CN103239590A (en) | Traditional Chinese medicine composition as well as preparation and application thereof | |
| CN1132597C (en) | The active part of golden pheasant as one Chinese medicine material and its application in preparing medicinal composite | |
| CN1985891B (en) | Compound Chinese medicine preparation with liver protecting function and its preparing process | |
| CN1475269A (en) | Rhizoma cimicifugae extract and its preparation method | |
| CN1876051A (en) | Chinese medicinal preparation for treating gynecological disease, its preparation process and quality control method | |
| CN101953887B (en) | Medicinal composition for preventing and treating diabetic complications and preparation method thereof | |
| CN104337884A (en) | Medicine composition for preventing and/or treating diabetes and complication of diabetes | |
| CN1491656A (en) | Medicinal use of asiatic centella extract containing asiaticoside and hydroxy asiaticoside | |
| CN1887324A (en) | Chinese composition and its prepn process and quality control method | |
| CN101411779B (en) | Chinese medicine effective component composition for treating liver cancer and method for preparing the same | |
| CN100488544C (en) | Improved Chinese medicinal capsule for treating climacteric syndrome | |
| CN101591374A (en) | A kind of steroidal compounds, its preparation method and contain their pharmaceutical composition and purposes | |
| CN100493522C (en) | Medicinal composition of oxymatrine and polysaccharide | |
| CN1272332C (en) | Red clover total flavone high content extract, preparation and application in pharmaceutical combination thereof | |
| CN102579959A (en) | Preparation method of medicinal composition for treating leukorrhea | |
| CN1589894A (en) | Medicinal composition for treating parafunctional metrorrhagia and its preparation method | |
| CN1839867A (en) | Medicinal composition with heat-clearing, fire-draining and detoxification function | |
| CN1220513C (en) | Proprietury Chinese medicine for stopping blood, analgesia, removing blood stasis and engender new and its preparation method | |
| CN101474315B (en) | Effective component group of stem-bark or root-bark of Daphne giraldii as well as preparation method and use thereof | |
| CN107865932B (en) | Traditional Chinese medicine composition with weight losing effect | |
| CN1209115C (en) | Active extracted composition of teasel root and notoginseng and use in medicine | |
| CN1416880A (en) | New use of powder for regulating liver and spleen and its active part | |
| CN1313111C (en) | Chinese medicinal extract for resisting osteoporosis and its preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20031231 Termination date: 20110302 |